There are two weirdly similar stories out today on how to shop thoughtfully for low-priced medicines, one from USA Today and one from the Boston Globe. These two pieces are

In some ways, I’ve given up on my dream that stories about beginning-of-the-year price changes for prescription drugs will be thoughtful. Yes, it would be nice if the stories were

Lord, this is lousy.  The New York Times is out with an explainer on why the United States has high drug prices. To the extent that there are myths around

Yesterday, feeling snarky, I asked a rhetorical question: “What has United done for anyone lately?” The point, in the context of yet another set of record profits for UnitedHealth Group,

/ So UnitedHealth Group made about $5.5 billion in pure profit last quarter, with revenues nearing $100 billion. A huge chunk of that came from its Optum unit. The company’s

Programming Note: Cost Curve is probably off tomorrow, almost certainly off Friday, and definity off Monday. I’ll catch everyone up next week. J.P. Morgan put, arguably, the two hottest companies

The thing about J.P. Morgan is that you can draw overbroad conclusions after just 24 hours. The deals have been announced. Bellwether companies have provided a baseline. Attendees are not

A reminder: I’ll be carting my “Pitching Pricing” trading cards around #JPM24 today. If you want a pack, let me know your whereabouts. It’s a short one today, because I’ll

Hoo boy … is there ever a lot on my mind. Let’s get going. Late-breaking news: the FDA has green-lit Florida’s plan to import medicines from other countries.  I’m on

First off, there aren’t capital letters big enough to express the CONGRATS I’d like to pass along to Adam Fein, whose Drug Channels Institute has been acquired by HMP Global.